Application of Explicit Process of Care Measurement to Rheumatoid Arthritis

Moving from Evidence to Practice

Published in: Arthritis Care and Research, v. 55, no. 6, Dec. 15, 2006, p. 884-891

Posted on RAND.org on January 01, 2006

by Katherine L. Kahn, Catherine MacLean, Honghu H. Liu, Laurence Rubenstein, Andrew L. Wong, Judith O. Harker, Wen-Pin Chen, Diane M. Fitzpatrick, Ken J. Bulpitt, Shana Traina, Brian Mittman, Bevra H. Hahn, H. E Paulus

Read More

Access further information on this document at www3.interscience.wiley.com

This article was published outside of RAND. The full text of the article can be found at the link above.

OBJECTIVE: To construct quality measures with measurement validity and meaning for clinicians. METHODS: The authors conducted a prospective cohort study of rates of change in disease-modifying antirheumatic drug (DMARD) and/or systemic corticosteroid drug or dose for 568 patients with rheumatoid arthritis (RA) across 6,159 clinical encounters within 12 months to examine how changes in clinical specifications change adherence. RESULTS: Rates of DMARD change were sensitive to specifications regarding the intensity of disease activity (severe or moderate), duration of specified disease activity, and length of the observation period. Over 12 months, the proportions of 377 patients with severe disease activity observed for 1-month, 2-month, and 3-month time blocks who had a change in DMARD drug or dose were 36%, 57%, and 74%, respectively. Over 12 months, a change in DMARD drug or dose was observed for 44%, 50%, and 68% of 377 patients with severe disease within 3 months, 6 months, and 12 months, respectively, of the patient meeting criteria for severe disease activity. A change in DMARD drug or dose was observed for 21%, 23%, and 34% of 149 patients with moderate disease activity within 3, 6, and 12 months, respectively, of the patient meeting criteria for moderate disease activity. CONCLUSION: Rates of pharmacologic interventions for patients with moderate and severe RA disease activity vary substantially by intensity and duration of disease activity and by duration of period for observing change. Lack of precision in explicit process criteria could substantially mislead comparisons of quality of care across comparison groups.

This report is part of the RAND Corporation external publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.